CasNo.1260141-27-2,Vonaprazan;5-(2-Fluorophenyl)-N-methyl-1-(3-pyridinylsulfonyl)-1H-pyrrole-3-methanamine 2-butenedioate (Vonoprazan);1-[5-(2-fluorophenyl)-1-pyridin-3-ylsulfonylpyrrol-3-yl]-N-methylmet,(1260141-27-2) Suppliers

1 Kilogram	Negotiable

Min.Order :1 Kilogram
Purity: 99%
Payment Terms : T/T

Keywords

Vonoprazan fumarate 1260141-27-2 Vonoprazan fumarate1260141-27-2

Quick Details

Appearance:solid
Application:intermediates
PackAge:According to your needs
ProductionCapacity:100|Metric Ton|Day
Storage:storage temperature
Transportation:By sea courier

Superiority:

Product Name:   Vonoprazan fumarate
Synonyms:   Vonaprazan;5-(2-Fluorophenyl)-N-methyl-1-(3-pyridinylsulfonyl)-1H-pyrrole-3-methanamine 2-butenedioate (Vonoprazan);1-[5-(2-fluorophenyl)-1-pyridin-3-ylsulfonylpyrrol-3-yl]-N-methylmethanamine;AK-438;Vonaprazan(TAK-438);vonoprazan(tak-438);Vonoprazan fumarate(TAK-438);vonoprazan(tak-438)1260141-27-2
CAS:   1260141-27-2
MF:   C21H20FN3O6S
MW:   461.4634032
EINECS:   250-635-4
Product Categories:   Vonoprazan;Inhibitors;API;1260141-27-2
Mol File:   1260141-27-2.mol

storage temp.    Store at -20°C
solubility    insoluble in H2O; insoluble in EtOH; ≥18.9 mg/mL in DMSO
form    solid
InChIKey   ROGSHYHKHPCCJW-WLHGVMLRSA-N
SMILES   N1(S(C2=CC=CN=C2)(=O)=O)C(C2=CC=CC=C2F)=CC(CNC)=C1.C(O)(=O)/C=C/C(O)=O

Details:

Description Vonoprazan fumarate (Takecab®), discovered and developed by Takeda and Otsuka, was approved by the PMDA of Japan in December 2014, and is indicated for the treatment of gastric ulcer, duodenal ulcer and reflux esophagitis. Vonoprazan fumarate has a novel mechanism of action called potassium-competitive acid blockers, which competitively inhibit the binding of potassium ions to H+, K+-ATPase (also known as the proton pump) in the final step of gastric acid secretion in gastric parietal cells. Vonoprazan does not inhibit Na+, K+-ATPase activity even at concentrations 500 times higher than that of their IC50 values against gastric H+, K+-ATPase activity. Furthermore, the drug is unaffected by the gastric secretory state, unlike PPIs.
Description Vonoprazan is a selective, reversible, and potassium-competitive proton pump inhibitor that inhibits gastric H+/K+ ATPase (IC50 = 17 nM) but does not inhibit porcine Na+/K+ ATPase activity when used at a concentration of 10 μM. It maintains its inhibitory effect in both weakly acidic (pH 6.5) and neutral (pH 7.5) conditions with IC50 values of 19 and 28 nM, respectively. In vivo, vonoprazan (1, 2, and 4 mg/kg) inhibits histamine-stimulated acid secretion in a dose-dependent manner in rats, with complete inhibition when administered at a dose of 4 mg/kg. It also inhibits acid secretion for more than 48 hours in dogs when administered at doses ranging from 0.1 to 1 mg/kg.